Literature DB >> 20193765

Modulating the p53 pathway.

Anwesha Dey1, David P Lane, Chandra S Verma.   

Abstract

p53 is a transcription factor that protects cells against stress, by modulating genes that induce growth arrest, repair, apoptosis, senescence or altered metabolism. Activation of p53 can potentially be used to modulate disease states. We describe here recent developments that attempt to modulate the function of p53 and outline strategies that are being investigated for pharmacological intervention in the p53 pathway. These include interruption of the interactions between p53 and its negative regulators, restabilization of mutant/misfolded p53, activation of p53 dependant transcription and modulation of p53 function systemically to affect the therapeutic profile of existing drugs. In addition the development of new animal models to investigate the above developments, including mice and zebrafish will be highlighted. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193765     DOI: 10.1016/j.semcancer.2010.02.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  10 in total

1.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

Review 3.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Authors:  Grzegorz M Popowicz; Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-21       Impact factor: 15.336

4.  Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.

Authors:  Hu Xiaowen; Sun Yi
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

5.  Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.

Authors:  Olga Catalina Rodriguez; Sujatra Choudhury; Vamsi Kolukula; Eveline E Vietsch; Jason Catania; Anju Preet; Katherine Reynoso; Jill Bargonetti; Anton Wellstein; Chris Albanese; Maria Laura Avantaggiati
Journal:  Cell Cycle       Date:  2012-11-14       Impact factor: 4.534

6.  Multifactorial origins of heart and gut defects in nipbl-deficient zebrafish, a model of Cornelia de Lange Syndrome.

Authors:  Akihiko Muto; Anne L Calof; Arthur D Lander; Thomas F Schilling
Journal:  PLoS Biol       Date:  2011-10-25       Impact factor: 8.029

7.  Value of glycogen synthase 2 in intrahepatic cholangiocarcinoma prognosis assessment and its influence on the activity of cancer cells.

Authors:  Sigen A; Huijun Wu; Xiaodong Wang; Xidong Wang; Jiarui Yang; Long Xia; Yijun Xia
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling.

Authors:  Franziska Wachter; Michaela Grunert; Cristina Blaj; David M Weinstock; Irmela Jeremias; Harald Ehrhardt
Journal:  Cell Commun Signal       Date:  2013-04-17       Impact factor: 5.712

Review 9.  Molecular mechanisms of etoposide.

Authors:  Alessandra Montecucco; Francesca Zanetta; Giuseppe Biamonti
Journal:  EXCLI J       Date:  2015-01-19       Impact factor: 4.068

10.  Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis.

Authors:  Takuya Kamio; Bai-wei Gu; Timothy S Olson; Yanping Zhang; Philip J Mason; Monica Bessler
Journal:  PLoS One       Date:  2016-04-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.